The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study.
Philip M W
PM
Bath
D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use*; D000991:Antithrombins / Q000009:adverse effects* / Q000627:therapeutic use*; D001120:Arginine / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008297:Male; D010875:Pipecolic Acids / Q000009:adverse effects* / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy*; D013449:Sulfonamides; D010959:Tissue Plasminogen Activator / Q000009:adverse effects* / Q000627:therapeutic use*
D000925:Anticoagulants; D000991:Antithrombins; D010875:Pipecolic Acids; D013449:Sulfonamides; D001120:Arginine; D010959:Tissue Plasminogen Activator; C031942:argatroban